People in the News

Mar 15, 2017

Brandi Davis-Dusenbery

Seven Bridges has promoted Brandi Davis-Dusenbery to CEO. She succeeds Co-founder Deniz Kural, who is assuming the role of executive chairman of the board of directors. Davis-Dusenbery was the former senior vice president of science and product for Seven Bridges. Prior to Seven Bridges, she worked as a fellow at Harvard University's Department of Stem Cell and Regenerative Biology.

Mar 09, 2017

Dan Szot

Cambridge Semantics has appointed Dan Szot as vice president of sales for the company's life science division. Szot comes to Cambridge Semantics from PerkinElmer, where he served at VP of sales. Prior to PerkinElmer, he served as VP of sales at Biovia.

Mar 08, 2017

Shawn Lynch

Shawn Lynch has resigned from his position as CFO of T2 Biosystems, effective immediately. According to a Form 8K the company filed this week with the US Securities and Exchange Commission, Lynch left for personal reasons and not as the result of a disagreement with management or the board.

Mar 08, 2017

Jay Shendure, Shankar Balasubramanian, Wolf Reik, Anjana Rao

Cambridge Epigenetix has appointed Jay Shendure, Shankar Balasubramanian, Wolf Reik, and Anjana Rao to its newly formed scientific advisory board. Balasubramanian, who co-founded the company and invented its proprietary 'TruMethyl' technology, will serve as chair. He is also the Herchel Smith Professor of Medicinal Chemistry at the University of Cambridge. Reik currently serves as head and associate director of the epigenetics program at the Babraham Institute in Cambridge. He also serves as scientific advisor to Cambridge Epigenetix, is an honorary professor of epigenetics at the University of Cambridge, and serves on the associate faculty at the Wellcome Trust Sanger Institute. Rao serves as professor and head of the Division of Signaling and Gene Expression at the La Jolla Institute and the Sanford Consortium for Regenerative Medicine in San Diego. Shendure serves as professor of genome sciences at the University of Washington.

Mar 08, 2017

Paul Dark, Angela Caliendo, Stephan Harbarth, Romney Humphries

DNAe has appointed Paul Dark, Angela Caliendo, Stephan Harbarth, and Romney Humphries to its newly formed clinical advisory board. Dark serves as chair of critical care medicine at the University of Manchester. He also works as a national research lead in critical care for the National Institute of Health Research and as a visiting professor at King's College London. Caliendo serves as a professor, executive vice chair of the department of medicine, and a director of the division of general internal medicine at the Warren Alpert Medical School of Brown University. She also serves as editor for the Journal of Clinical Microbiology, chair of the Microbiology Medical Devices panel for the FDA, and serves on the board of directors of the Infectious Diseases Society of America. Harbarth serves as an associate professor at the University of Geneva and senior consultant at the Geneva University Hospitals. Humphries is an assistant professor in the department of pathology and laboratory medicine in the David Geffen School of Medicine at the University of California, Los Angeles.

Mar 07, 2017

Ann Hanham

Ann Hanham has been appointed the chair of HTG Molecular Diagnostics' board. Hanham has more than 15 years of experience in the life science investment sector as a founding member and managing partner of BAR Capital Management. Before that, she was a managing director and general partner of Burrill & Co. 

Mar 06, 2017

Karen Chapman

Oncocyte has announced the resignation of its vice president of research, Karen Chapman in a filing with the US Securities and Exchange Commission. The firm said Chapman's employment will terminate on March 22.
 
Under an employment termination and release agreement, Oncocyte said it has agreed to extend the expiration date of Chapman's employee stock options to February 28, 2018, with the agreement that she not offer, sell, or otherwise dispose of any "Lock-up Shares," before May 31, 2017 without the company's consent.
Mar 02, 2017

Rudi Pauwels

Biocartis has announced that Founder Rudi Pauwels will step down from his position as CEO and take on the role of chairman of a new strategy committee of the board. Deputy CEO Hilde Windels will assume the role of CEO until a permanent successor is found.

Mar 01, 2017

David Roth, Pilar de la Huerta

Sygnis has appointed David Roth as its new CFO. In this role, Roth will be in charge of financial strategy and accounting processes. Former CFO Pilar de la Huerta will remain with the company, serving as co-CEO with Heikki Lanckriet and as chief business development officer. Roth comes to Sygnis with over 20 years of financial management experience focused on the healthcare sector, and has spent the last several years serving as CFO for several international organizations.

Mar 01, 2017

Dion Weisler

Thermo Fisher Scientific has appointed Dion Weisler to its board of directors. Weisler's appointment brings the total number of board members to 12. Currently, he serves as president and CEO of Hewlett-Packard, and also serves on the company's board of directors. He previously served as executive VP of HP's printing and personal systems business. Before joining HP, he served as VP and chief operating officer of product and mobile internet digital home groups at Lenovo.

Mar 01, 2017

Dirk van den Boom

CombiMatrix has appointed Dirk van den Boom to its board of directors. Dirk most recently served as president, CEO, and director of Sequenom, prior to its acquisition by LabCorp in September 2016. During his 18 year tenure at Sequenom, he held positions of increasing responsibility including chief scientific and strategy officer, executive VP of research and development, chief technology officer, and senior VP of research and development.

Mar 01, 2017

Hannes Smarason, John Long, Alex Fowkes

WuXi AppTec group subsidiary, WuXi NextCode, has appointed Hannes Smarason as CEO, John Long as CFO, and Alex Fowkes as chief operating officer. Smarason has been serving as COO for WuXi NextCode for the past two years. He co-founded NextCode Health in 2013, a spinout from deCode genetics, and he oversaw WuXi AppTec's aquisition of NextCode in 2015 and the company's merger with the WuXi Genome Center. Long has served as WuXi AppTec's senior vice president of finance since 2013. Prior to joining the company, he served in senior roles at Willis Group, Tyco International, and Lucent Technologies. Fowkes joined WuXi AppTec in 2012 where he initially led corporate development. He most recently served as senior vice president of commercial operations. Prior to WuXi, he served in a variety of roles for Pfizer in the US, UK, Australia, and China over 14 years.

Mar 01, 2017

Leroy Hood

BGI has appointed Leroy Hood to its scientific advisory board. In this role, Hood will provide professional advice to the company's genetic technology development efforts based on his experience and insights in the field. Currently, he is the president and co-founder of the Institute for Systems Biology, and senior vice president and chief scientific officer of Providence St. Joseph Health.

Feb 21, 2017

Raymond Stevens

Raymond Stevens has been appointed to Danaher's board of directors. Stevens currently serves as provost professor of biological sciences and chemistry and director of the Bridge Institute at the University of Southern California. Before that, he was a professor of molecular biology and chemistry at the Scripps Research Institute. 

Feb 20, 2017

John Thompson

Illumina has named John Thompson to its board of directors, effective May 3. Thompson is chairman of the board at Microsoft. He has also served as CEO at Symantec and Virtual Instruments, has held various roles over 28 years at IBM, and has served on the boards of Symantec, Northern Indiana Public Service Company, Fortune Brands, Seagate Technologies, and UPS. He is a member of the board of trustees for the Wetlands America Trust and was formerly a member of the national board of Teach for America. In addition, he has served on several government commissions, including the Financial Crisis Inquiry Commission, the National Infrastructure Advisory Council, and the Silicon Valley Blue Ribbon Task Force on Aviation Security and Technology. 

Feb 17, 2017

Igor Gitelman

Cancer Genetics has appointed Igor Gitelman the firm's principal accounting officer, replacing Victor Cross who had been promoted to that position in early January. The company said Cross left for family reasons. From late 2005 to late 2016 Gitelman was assistant vice president of finance and tax at BioReference Laboratories. 

Feb 17, 2017

Michael Terry

Biocept has appointed Michael Terry to the newly created position of senior vice president of commercial operations, where he will lead the company's commercial organization and oversee its business development initiatives. Prior to joining Biocept, Terry served as executive vice president of commercial operations and corporate development at liquid biopsy firm Trovagene. He has also served as executive vice president of Sequenom as CEO of neonatal diagnostics startup Ligand Dx, and has worked for Lumenis, GE Healthcare, and Aspect Medical Systems, among others.

Feb 17, 2017

Frederick Eibel

MolecularMD has appointed Frederick Eibel as senior vice president and chief marketing officer. Eibel joins MolecularMD from Wren Laboratories, where he served as senior vice president. Before his time at Wren, Eibel spent 23 years at Roche Diagnostics in various roles. He has also held leadership roles at Rain Dance Technologies, Sequenom, Life Technologies, and Gen Probe.

Feb 17, 2017

George Davis

Perthera has appointed George Davis to its board of directors. Davis currently serves as CEO of Gemstone Biotherapeutics. Previously, he served as president and vice chairman of Aether Systems. He has also served as CEO and director of Avatech Solutions.

Feb 16, 2017

Leeona Galligan

Almac Diagnostics has appointed Leeona Galligan as VP of UK Operations. She will be responsible for all UK-based operations, including commercial biomarker discovery, CLIA/FDA compliant analytical validation, downstream clinical testing, manufacturing and shipping of clinical specimens, and release of controls and reagents for registrational clinical trials. Galligan joined Almac in September 2009 as a senior scientist. She was appointed clinical testing laboratory manager in 2012 and was subsequently promoted to head of UK lab-based operations.

Feb 14, 2017

David Agus

David Agus has joined personalized oncology firm Tempus as Chairman of the firm's scientific advisory board. He is currently a Professor at the University of Southern California and head of its Ellison Institute for Transformative Medicine. Agus holds a medical degree from the University of Pennsylvania and completed a fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center.

Feb 10, 2017

Amy Sturm

Geisinger's Genomic Medicine Institute has appointed Amy Sturm as director of cardiovascular genomic counseling. Sturm also serves as a member of the ClinGen Cardiovascular Clinical Domain Working Group. She joins Geisinger from Ohio State University, where she served as associate professor in the Division of Human Genetics at OSU's Wexner Medical Center. She has served on the board of directors of the National Society of Genetic Counselors, and works extensively with the Familial Hypercholesterolemia Foundation and the Sudden Arrhythmia Death Syndromes Foundation.

Feb 09, 2017

Yaniv Erlich

MyHeritage has appointed Yaniv Erlich as chief science officer. He will lead the company's scientific development and strategy for its MyHeritage DNA service. Erlich comes to MyHeritage from Columbia University, where he served as assistant professor of computer science and computational biology. He has also served as a core member of the New York Genome Center, the principal investigator and Whitehead Fellow at MIT's Whitehead Institute, founder of DNA.LAND, and the principal investigator of the Erlich DNA lab.

Feb 09, 2017

Bradford Crutchfield

10x Genomics has appointed Bradford Crutchfield to the position of chief commercial officer, replacing John Pouk, who had been serving as the company's interim CCO. Pouk will stay on as senior vice president of commercial operations. Crutchfield previously served as senior vice president of Qiagen's life sciences business. He has also served as vice president and general manager of Illumina's Europe, Middle East, and Africa operations, as director of NanoString Technologies, and in various roles at Bio-Rad Laboratories. 

Feb 09, 2017

Richard Dennis

Proteome Sciences said this week that it has appointed Richard Dennis as the company's first chief commercial officer, effective beginning in April. Dennis most recently served as director of international sales at Quanterix. He also previously served as vice president of international commercial operations at Bioscale, and director of sales at Meso Scale Discovery.

Pages

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.